Ira Winer, MD, PhD, Talks Best Data to Come Out of SGO 2022

During The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer, CancerNetwork® spoke with Ira Winer, MD, PhD, FACOG, a gynecologic oncologist at the Karmanos Cancer Center and associate professor in the Division of Gynecologic Oncology at Wayne State University in Detroit, about the future of ovarian cancer treatment and ongoing trials that were presented at the conference that he’s eager to see results of.

Transcript:

The most interesting thing about SGO this year was the trajectory [showing] how much we’re moving towards targeted therapies and individualized therapies, even in the IO [immuno-oncology] realm, as well as the non-IO realm. If you listen, especially to some of the plenaries, you could hear that we’re really digging into the mechanistic complex of how these [tumors] work in terms of how their disease responds to these treatments. [Given that], we’ll be able to better target the cancers in the future, but also choose the right patients for the right treatment. That is the most exciting. Over the course of SGO, [presentations continually proved] how things are moving in that direction. Even in the IO realm, we had some secondary analyses of various trials to look at why perhaps patients responded versus didn’t respond. That’s going to allow us to better design our trials in the future, and also hopefully to better sequence treatments, whether it’s IO or not. That was the most exciting thing about this SGO.